株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リウマチ様関節疾患向けマーカー検査製品:パイプライン分析

Rheumatoid - Inflammatory Diseases Markers Tests - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 344269
出版日 ページ情報 英文 161 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.37円で換算しております。
Back to Top
リウマチ様関節疾患向けマーカー検査製品:パイプライン分析 Rheumatoid - Inflammatory Diseases Markers Tests - Medical Devices Pipeline Assessment, 2017
出版日: 2017年09月08日 ページ情報: 英文 161 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発中の、リウマチ様関節疾患向けマーカー検査製品 (試薬など) のパイプライン製品情報について分析し、治験/製品開発の全体的な進行状況や、段階別・分野別・地域別の詳細動向、企業別・製品別の詳細情報 (治験の進行段階、開始/終了時期、認証見通しなど)、昨今の製品開発の動き・業界動向などを盛り込んでお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 開発中の製品

  • パイプライン製品:開発段階別
  • パイプライン製品:分野別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:認証時期別 (推定)

第4章 リウマチ様関節疾患向けマーカー検査製品:現在開発中のパイプライン製品 (企業別)

  • リウマチ様関節疾患向けマーカー検査製品の開発企業:パイプライン製品 (開発段階別)
  • リウマチ様関節疾患向けマーカー検査製品:開発段階別のパイプライン製品の一覧

第5章 リウマチ様関節疾患向けマーカー検査製品の企業・製品の概要

  • Abcodia Ltd.
    • パイプライン製品および現在進行中の治験の概要
  • Albert-Ludwigs-Universitat Freiburg
  • Analyticon Biotechnologies AG
  • AnaMar AB
  • Bayerische Patentallianz GmbH
  • Beckman Coulter, Inc.
  • BioSIMS
  • CD Diagnostics, Inc.
  • Chronix Biomedical, Inc.
  • Consejo Superior de Investigaciones Cientificas
  • Crescendo Bioscience, Inc.
  • DIESSE Diagnostica Senese S.p.A.
  • DSX Therapeutics
  • Fundacio Clinic per a la Recerca Biomedica
  • Genalyte, Inc.
  • GeneNews Limited
  • Ghent University
  • Ignyta, Inc.
  • Institut National de la Sante et de la Recherche Medicale
  • KineMed, Inc.
  • Louisville Bioscience, Inc.
  • Myriad Genetics, Inc.
  • Proplex Technologies, Llc
  • Protagen AG
  • Selventa
  • Siemens Healthcare Diagnostics Inc.
  • Singulex, Inc.
  • SomaLogic, Inc.
  • SQI Diagnostics Inc.
  • The Binding Site Group Ltd.
  • The Johns Hopkins University
  • Thermo Fisher Scientific Inc.
  • Toscana Biomarkers Srl
  • University of Aberdeen
  • University of Manchester
  • University of Missouri
  • University of Oxford
  • University of Rochester
  • University of Warwick
  • University Rovira i Virgili

第6章 リウマチ様関節疾患向けマーカー検査製品:昨今の市場動向

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0438EPD

GlobalData's Medical Devices sector report, "Rheumatoid - Inflammatory Diseases Markers Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Rheumatoid - Inflammatory Diseases Markers Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Rheumatoid - Inflammatory Diseases Markers Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Rheumatoid - Inflammatory Diseases Markers Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Rheumatoid - Inflammatory Diseases Markers Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Rheumatoid - Inflammatory Diseases Markers Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Introduction 10

  • 2.1 Rheumatoid - Inflammatory Diseases Markers Tests Overview 10

3 Products under Development 11

  • 3.1 Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Stage of Development 11
  • 3.2 Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Segment 12
  • 3.3 Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Territory 13
  • 3.4 Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Regulatory Path 14
  • 3.5 Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Estimated Approval Date 15

4 Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products under Development by Companies 16

  • 4.1 Rheumatoid - Inflammatory Diseases Markers Tests Companies - Pipeline Products by Stage of Development 16
  • 4.2 Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Stage of Development 18

5 Rheumatoid - Inflammatory Diseases Markers Tests Companies and Product Overview 20

  • 5.1 Abcodia Ltd Company Overview 20
    • 5.1.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.2 Albert Ludwigs University of Freiburg Company Overview 21
    • 5.2.1 Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.3 Analyticon Biotechnologies AG Company Overview 22
    • 5.3.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.4 AnaMar AB Company Overview 23
    • 5.4.1 AnaMar AB Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.5 Arizona State University Company Overview 24
    • 5.5.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.6 AXO Science SAS Company Overview 25
    • 5.6.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.7 Bayerische Patentallianz GmbH Company Overview 26
    • 5.7.1 Bayerische Patentallianz GmbH Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.8 Beckman Coulter Inc Company Overview 27
    • 5.8.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.9 BioSIMS Company Overview 36
    • 5.9.1 BioSIMS Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.10 Boditech Med Inc Company Overview 37
    • 5.10.1 Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.11 CD Diagnostics, Inc. Company Overview 38
    • 5.11.1 CD Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.12 CDI Laboratories Inc Company Overview 39
    • 5.12.1 CDI Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.13 Chronix Biomedical Inc Company Overview 40
    • 5.13.1 Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.14 Consejo Superior de Investigaciones Cientificas Company Overview 41
    • 5.14.1 Consejo Superior de Investigaciones Cientificas Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.15 DxTerity Diagnostics Inc Company Overview 42
    • 5.15.1 DxTerity Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.16 EKF Diagnostics Holdings Plc Company Overview 43
    • 5.16.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.17 EMD Millipore Corp Company Overview 44
    • 5.17.1 EMD Millipore Corp Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.18 Epinex Diagnostics Inc Company Overview 45
    • 5.18.1 Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.19 Firalis SAS Company Overview 46
    • 5.19.1 Firalis SAS Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.20 French National Institute of Health and Medical Research Company Overview 47
    • 5.20.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.21 Fundacio Clinic per a la Recerca Biomedica Company Overview 48
    • 5.21.1 Fundacio Clinic per a la Recerca Biomedica Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.22 Genalyte, Inc. Company Overview 50
    • 5.22.1 Genalyte, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.23 GeneNews Ltd Company Overview 51
    • 5.23.1 GeneNews Ltd Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.24 Ghent University Company Overview 52
    • 5.24.1 Ghent University Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.25 Ignyta Inc Company Overview 53
    • 5.25.1 Ignyta Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.26 Iquity Labs Inc Company Overview 56
    • 5.26.1 Iquity Labs Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.27 John Hopkins University Company Overview 57
    • 5.27.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.28 KineMed Inc Company Overview 59
    • 5.28.1 KineMed Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.29 LifeAssays AB Company Overview 60
    • 5.29.1 LifeAssays AB Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.30 Louisville Bioscience, Inc. Company Overview 61
    • 5.30.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.31 Medica Corp Company Overview 62
    • 5.31.1 Medica Corp Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.32 Myriad Genetics Inc Company Overview 63
    • 5.32.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.33 Proplex Technologies Llc Company Overview 64
    • 5.33.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.34 Protagen AG Company Overview 65
    • 5.34.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.35 Queen Mary University of London Company Overview 67
    • 5.35.1 Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.36 Research & Diagnostic Antibodies LLC Company Overview 68
    • 5.36.1 Research & Diagnostic Antibodies LLC Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.37 Selventa Inc Company Overview 69
    • 5.37.1 Selventa Inc Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.38 SomaLogic Inc Company Overview 70
    • 5.38.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.39 SQI Diagnostics Inc Company Overview 71
    • 5.39.1 SQI Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 71
  • 5.40 The Binding Site Group Ltd Company Overview 72
    • 5.40.1 The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.41 Thermo Fisher Scientific Inc Company Overview 74
    • 5.41.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 74
  • 5.42 Toscana Biomarkers Srl Company Overview 77
    • 5.42.1 Toscana Biomarkers Srl Pipeline Products & Ongoing Clinical Trials Overview 77
  • 5.43 University Health Network Company Overview 78
    • 5.43.1 University Health Network Pipeline Products & Ongoing Clinical Trials Overview 78
  • 5.44 University of Aberdeen Company Overview 79
    • 5.44.1 University of Aberdeen Pipeline Products & Ongoing Clinical Trials Overview 79
  • 5.45 University of Manchester Company Overview 80
    • 5.45.1 University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 80
  • 5.46 University of Oxford Company Overview 81
    • 5.46.1 University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 81
  • 5.47 University of Rochester Company Overview 82
    • 5.47.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 82
  • 5.48 University of Warwick Company Overview 83
    • 5.48.1 University of Warwick Pipeline Products & Ongoing Clinical Trials Overview 83
  • 5.49 University Rovira i Virgili Company Overview 84
    • 5.49.1 University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview 84

6 Rheumatoid - Inflammatory Diseases Markers Tests- Recent Developments 85

  • 6.1 Aug 24, 2017: SQI Diagnostics Reports Third Quarter 2017 Results 85
  • 6.2 Aug 22, 2017: Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 86
  • 6.3 Aug 15, 2017: GeneNews Announces Q2-2017 Financial Results & Provides Progress Update 87
  • 6.4 Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 88
  • 6.5 Aug 03, 2017: Alere Reports Second Quarter 2017 Financial Results 89
  • 6.6 Aug 03, 2017: Bio-Rad Reports Second-Quarter 2017 Financial Results 89
  • 6.7 Jul 26, 2017: Thermo Fisher Scientific Reports Second Quarter 2017 Results 90
  • 6.8 Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% 92
  • 6.9 Jul 13, 2017: Dr. Jaymie Sawyer, Vice President of R&D, Transitions to Lead Scientific Advisory Committee 93
  • 6.10 Jun 30, 2017: GeneNews Announces Election of Directors 93
  • 6.11 Jun 29, 2017: HYCOR Biomedical Announces Senior Level Appointments to Management Team 93
  • 6.12 Jun 15, 2017: Crescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra DA at the 2017 Annual European Congress of Rheumatology 94
  • 6.13 Jun 14, 2017: Alere Reports First Quarter 2017 Financial Results 95
  • 6.14 Jun 08, 2017: Crescendo Bioscience Announces Six Studies with Vectra DA Will Be Presented at the 2017 Annual European Congress of Rheumatology 96
  • 6.15 Jun 05, 2017: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2016 Financial Results 97
  • 6.16 May 22, 2017: Alere Provides Preliminary Unaudited Financial Results 98
  • 6.17 May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 99
  • 6.18 May 11, 2017: GeneNews Announces Q1-2017 Financial Results & Provides Progress Update 100
  • 6.19 May 10, 2017: SQI Diagnostics Reports Second Quarter 2017 Results 101
  • 6.20 May 04, 2017: Bio-Rad Reports First-Quarter 2017 Financial Results 103
  • 6.21 May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 104
  • 6.22 May 01, 2017: Ignyta Announces First Quarter 2017 Company Highlights and Financial Results 106
  • 6.23 Apr 27, 2017: THERADIAG Announces First-quarter 2017 Revenues 107
  • 6.24 Apr 27, 2017: Theradiag: First-Quarter 2017 Revenues 108
  • 6.25 Apr 26, 2017: Thermo Fisher Scientific Reports First Quarter 2017 Results 108
  • 6.26 Apr 24, 2017: Seno Medical Instruments Appoints Ann Waterhouse as VP, Quality Assurance and Regulatory Affairs 110
  • 6.27 Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 110
  • 6.28 Apr 05, 2017: SomaLogic announces the appointment of long-time Board member as Chief Executive Officer 111
  • 6.29 Apr 03, 2017: GeneNews Announces Fourth Quarter and Full Year 2016 Financial Results 112
  • 6.30 Mar 20, 2017: EKF Diagnostics Holdings: Final results 113
  • 6.31 Mar 14, 2017: Ignyta Announces Full Year 2016 Company Highlights and Financial Results 113
  • 6.32 Mar 13, 2017: Bio-Rad Intends to Propose Three New Independent Directors 115
  • 6.33 Mar 13, 2017: Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day 116
  • 6.34 Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 117
  • 6.35 Mar 09, 2017: Alere Provides Update on Arriva Medical 118
  • 6.36 Mar 01, 2017: Thermo Fisher Scientific Elects New Director to Board 118
  • 6.37 Mar 01, 2017: Appointment of Dominique Costantini and Dominique Takizawa to Theradiag's Board of Directors 119
  • 6.38 Mar 01, 2017: THERADIAG: Full-year 2016 results 120
  • 6.39 Feb 23, 2017: Ablynx Announces 2016 Full Year Results 122
  • 6.40 Feb 23, 2017: VBio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 123
  • 6.41 Feb 23, 2017: Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 125
  • 6.42 Feb 21, 2017: SQI Diagnostics Reports First Quarter 2017 Results 127
  • 6.43 Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 128
  • 6.44 Jan 31, 2017: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2016 Results 129
  • 6.45 Jan 23, 2017: ISO 17025 Accreditation for Microbiology Manufacturing Site Offers Increased Confidence to Microbiology Testing Laboratories 132
  • 6.46 Jan 18, 2017: SQI Diagnostics Announces Change to its Board of Directors 132
  • 6.47 Jan 05, 2017: Metabolon to Work With InnVentis to Study Chronic Inflammatory Diseases 133
  • 6.48 Jan 04, 2017: Alere Laboratory Receives ABFT Accreditation 133
  • 6.49 Jan 04, 2017: Alere Provides Update on Arriva Medical 134
  • 6.50 Dec 28, 2016: Alere Provides Update on Arriva Medical 134
  • 6.51 Dec 27, 2016: Positive Clinical Utility Results of Crescendo's Vectra DA Test for Rheumatoid Arthritis Published in the Journal Arthritis & Rheumatology 135
  • 6.52 Dec 22, 2016: United Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra DA Test for Adults with Rheumatoid Arthritis 136
  • 6.53 Dec 20, 2016: Singulex Opens European Office and Advances IVD System Evaluation 136
  • 6.54 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe 137
  • 6.55 Dec 12, 2016: Ignyta appoints new board member 138
  • 6.56 Dec 12, 2016: Ignyta Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals to Board of Directors 138
  • 6.57 Dec 08, 2016: Khang & Khang Announces Securities Class Action Lawsuit against Alere and Reminds Investors with Losses to Contact the Firm 139
  • 6.58 Dec 07, 2016: IQuity appoints new board member 139
  • 6.59 Dec 07, 2016: Abbott Seeks To Terminate Alere Acquisition 140
  • 6.60 Nov 23, 2016: Ablynx Announces Results For The First Nine Months Of 2016 And A Year-To-Date Business Update 140
  • 6.61 Nov 12, 2016: Crescendo Bioscience Announces Four Studies with Vectra DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting 143
  • 6.62 Nov 11, 2016: GeneNews Announces Q3-2016 Financial Results and Provides Corporate Update 144
  • 6.63 Nov 10, 2016: VolitionRx Announces Third Quarter 2016 Financial Results and Business Update 146
  • 6.64 Nov 07, 2016: Ignyta Announces Third Quarter 2016 Company Highlights and Financial Results 147
  • 6.65 Nov 04, 2016: Alere Reports Third Quarter 2016 Financial Results 148
  • 6.66 Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent 148
  • 6.67 Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results 149
  • 6.68 Oct 27, 2016: Thermo Fisher Scientific Reports Third Quarter 2016 Results 150
  • 6.69 Oct 13, 2016: THERADIAG: Very strong revenue growth at end-September 2016: +31% 152
  • 6.70 Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy 153
  • 6.71 Sep 14, 2016: THERADIAG: First-half 2016 Revenues and Results 153
  • 6.72 Sep 14, 2016: Ignyta to Present at 2016 Silicon Valley Bank Healthcare Capital and Connections Summit 154
  • 6.73 Sep 12, 2016: EKF Diagnostics Holdings: Half-year Report 155

7 Appendix 158

  • 7.1 Methodology 158
  • 7.2 About GlobalData 161
  • 7.3 Contact Us 161
  • 7.4 Disclaimer 161

List of Tables

1.1 List of Tables

  • Table 1: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Stage of Development 11
  • Table 2: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Segment 12
  • Table 3: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Territory 13
  • Table 4: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Regulatory Path 14
  • Table 5: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Estimated Approval Date 15
  • Table 6: Rheumatoid - Inflammatory Diseases Markers Tests Companies - Pipeline Products by Stage of Development 16
  • Table 7: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Stage of Development 18
  • Table 8: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 9: Molecular Biomarker - Rheumatoid Arthritis - Product Status 20
  • Table 10: Molecular Biomarker - Rheumatoid Arthritis - Product Description 20
  • Table 11: Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 12: Diagnostic Kit - Rheumatoid Arthritis - Product Status 21
  • Table 13: Diagnostic Kit - Rheumatoid Arthritis - Product Description 21
  • Table 14: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 15: Turbitex ASL - Product Status 22
  • Table 16: Turbitex ASL - Product Description 22
  • Table 17: AnaMar AB Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 18: NeoSix Biomarker Assay - Product Status 23
  • Table 19: NeoSix Biomarker Assay - Product Description 23
  • Table 20: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 21: Diagnostic Test - Rheumatoid Arthritis - Product Status 24
  • Table 22: Diagnostic Test - Rheumatoid Arthritis - Product Description 24
  • Table 23: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 24: Multiplexed Detection - CRP - Product Status 25
  • Table 25: Multiplexed Detection - CRP - Product Description 25
  • Table 26: Bayerische Patentallianz GmbH Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 27: Prognostic Test - Rheumatoid Arthritis - Product Status 26
  • Table 28: Prognostic Test - Rheumatoid Arthritis - Product Description 26
  • Table 29: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 30: AU480 Clinical System - anti-CCP Assay - Product Status 27
  • Table 31: AU480 Clinical System - anti-CCP Assay - Product Description 28
  • Table 32: AU5810 Clinical System - anti-CCP Assay - Product Status 28
  • Table 33: AU5810 Clinical System - anti-CCP Assay - Product Description 28
  • Table 34: AU5820 Clinical System - anti-CCP Assay - Product Status 29
  • Table 35: AU5820 Clinical System - anti-CCP Assay - Product Description 29
  • Table 36: AU5830 Clinical System - anti-CCP Assay - Product Status 29
  • Table 37: AU5830 Clinical System - anti-CCP Assay - Product Description 30
  • Table 38: AU5840 Clinical System - anti-CCP Assay - Product Status 30
  • Table 39: AU5840 Clinical System - anti-CCP Assay - Product Description 30
  • Table 40: AU680 Clinical System - anti-CCP Assay - Product Status 31
  • Table 41: AU680 Clinical System - anti-CCP Assay - Product Description 31
  • Table 42: UniCel DxC 600 - anti-CCP Assay - Product Status 31
  • Table 43: UniCel DxC 600 - anti-CCP Assay - Product Description 32
  • Table 44: UniCel DxC 600i Synchron Access - anti-CCP Assay - Product Status 32
  • Table 45: UniCel DxC 600i Synchron Access - anti-CCP Assay - Product Description 32
  • Table 46: UniCel DxC 680i Synchron Access Clinical System - anti-CCP Assay - Product Status 33
  • Table 47: UniCel DxC 680i Synchron Access Clinical System - anti-CCP Assay - Product Description 33
  • Table 48: UniCel DxC 800 Synchron Access Clinical System - anti-CCP Assay - Product Status 33
  • Table 49: UniCel DxC 800 Synchron Access Clinical System - anti-CCP Assay - Product Description 34
  • Table 50: UniCel DxC 860i Synchron Access Clinical System - anti-CCP Assay - Product Status 34
  • Table 51: UniCel DxC 860i Synchron Access Clinical System - anti-CCP Assay - Product Description 34
  • Table 52: UniCel DxC 880i Synchron Access Clinical System - anti-CCP Assay - Product Status 35
  • Table 53: UniCel DxC 880i Synchron Access Clinical System - anti-CCP Assay - Product Description 35
  • Table 54: BioSIMS Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 55: DigiPLEX Analyzer - Rheumatology Assay - Product Status 36
  • Table 56: DigiPLEX Analyzer - Rheumatology Assay - Product Description 36
  • Table 57: Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 58: AFIAS-6 RF IgM Assay - Product Status 37
  • Table 59: AFIAS-6 RF IgM Assay - Product Description 37
  • Table 60: CD Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 61: Cygnasure Diagnostic Immunoassay - Rheumatoid Arthritis - Product Status 38
  • Table 62: Cygnasure Diagnostic Immunoassay - Rheumatoid Arthritis - Product Description 38
  • Table 63: CDI Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 64: Diagnostic Test - Rheumatoid Arthritis - Product Status 39
  • Table 65: Diagnostic Test - Rheumatoid Arthritis - Product Description 39
  • Table 66: Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 67: Companion Diagnostic Test - Rheumatoid Arthritis - Product Status 40
  • Table 68: Companion Diagnostic Test - Rheumatoid Arthritis - Product Description 40
  • Table 69: Consejo Superior de Investigaciones Cientificas Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 70: Diagnostic Assay - Rheumatoid Arthritis - Product Status 41
  • Table 71: Diagnostic Assay - Rheumatoid Arthritis - Product Description 41
  • Table 72: DxTerity Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 73: RADx - Product Status 42
  • Table 74: RADx - Product Description 42
  • Table 75: EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 76: Quo-Lab - C-Reactive Protein - Product Status 43
  • Table 77: Quo-Lab - C-Reactive Protein - Product Description 43
  • Table 78: EMD Millipore Corp Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 79: Erenna System - Rheumatoid Arthritis - Product Status 44
  • Table 80: Erenna System - Rheumatoid Arthritis - Product Description 44
  • Table 81: Epinex Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 82: Epinex G1A - Rheumatoid Arthritis Rapid Diagnostic Test - Product Status 45
  • Table 83: Epinex G1A - Rheumatoid Arthritis Rapid Diagnostic Test - Product Description 45
  • Table 84: Firalis SAS Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 85: Biomarker Test - Rheumatoid Arthritis - Product Status 46
  • Table 86: Biomarker Test - Rheumatoid Arthritis - Product Description 46
  • Table 87: French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 88: GPI Biomarker Assay - Arthritis - Product Status 47
  • Table 89: GPI Biomarker Assay - Arthritis - Product Description 47
  • Table 90: Fundacio Clinic per a la Recerca Biomedica Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 91: Diagnostic Assay - Rheumatoid Arthritis - Product Status 48
  • Table 92: Diagnostic Assay - Rheumatoid Arthritis - Product Description 48
  • Table 93: Early Diagnostic Assay - Rheumatoid Arthritis - Product Status 49
  • Table 94: Early Diagnostic Assay - Rheumatoid Arthritis - Product Description 49
  • Table 95: Genalyte, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 96: Maverick Rheumatoid Arthritis Multiplex Assay Kit - Product Status 50
  • Table 97: Maverick Rheumatoid Arthritis Multiplex Assay Kit - Product Description 50
  • Table 98: GeneNews Ltd Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 99: Biomarker Diagnostic Test - Rheumatoid Arthritis - Product Status 51
  • Table 100: Biomarker Diagnostic Test - Rheumatoid Arthritis - Product Description 51
  • Table 101: Ghent University Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 102: Biomarker Test - Spondyloarthropathy - Product Status 52
  • Table 103: Biomarker Test - Spondyloarthropathy - Product Description 52
  • Table 104: Ignyta Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 105: CLIA Waived Diagnostic Test - Rheumatoid Arthritis - Product Status 53
  • Table 106: CLIA Waived Diagnostic Test - Rheumatoid Arthritis - Product Description 53
  • Table 107: TrailblazeDx Test - Rheumatoid Arthritis - Product Status 54
  • Table 108: TrailblazeDx Test - Rheumatoid Arthritis - Product Description 54
  • Table 109: TrailblazeTx Test - Rheumatoid Arthritis - Product Status 54
  • Table 110: TrailblazeTx Test - Rheumatoid Arthritis - Product Description 55
  • Table 111: Iquity Labs Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 112: IsolateRheum - Product Status 56
  • Table 113: IsolateRheum - Product Description 56
  • Table 114: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 115: Anti-PAD3 Based Diagnostic Assay - Rheumatoid Arthritis - Product Status 57
  • Table 116: Anti-PAD3 Based Diagnostic Assay - Rheumatoid Arthritis - Product Description 57
  • Table 117: Biomarker Assay - Rheumatoid Arthritis - Product Status 58
  • Table 118: Biomarker Assay - Rheumatoid Arthritis - Product Description 58
  • Table 119: KineMed Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 120: Diagnostic Assay - Collagen Synthesis - Product Status 59
  • Table 121: Diagnostic Assay - Collagen Synthesis - Product Description 59
  • Table 122: LifeAssays AB Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 123: LifeAssays hsCRP - Product Status 60
  • Table 124: LifeAssays hsCRP - Product Description 60
  • Table 125: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 126: Rheumatoid Arthritis pT Autoimmune Test - Product Status 61
  • Table 127: Rheumatoid Arthritis pT Autoimmune Test - Product Description 61
  • Table 128: Medica Corp Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 129: EasyRA Analyzer - RF Assay - Product Status 62
  • Table 130: EasyRA Analyzer - RF Assay - Product Description 62
  • Table 131: Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 132: myPath Psoriatic Arthritis - Product Status 63
  • Table 133: myPath Psoriatic Arthritis - Product Description 63
  • Table 134: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 135: Biomarker Diagnostic Test - Rheumatoid Arthritis - Product Status 64
  • Table 136: Biomarker Diagnostic Test - Rheumatoid Arthritis - Product Description 64
  • Table 137: Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 138: Multilisa RA - Product Status 65
  • Table 139: Multilisa RA - Product Description 65
  • Table 140: NavigAID Rheumatoid Arthritis - Product Status 66
  • Table 141: NavigAID Rheumatoid Arthritis - Product Description 66
  • Table 142: Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 143: Biomarker Assay - Rheumatoid Arthritis - Product Status 67
  • Table 144: Biomarker Assay - Rheumatoid Arthritis - Product Description 67
  • Table 145: Research & Diagnostic Antibodies LLC Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 146: Diagnostic Test - Rheumatoid Arthritis - Product Status 68
  • Table 147: Diagnostic Test - Rheumatoid Arthritis - Product Description 68
  • Table 148: Selventa Inc Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 149: Clarify - Rheumatoid Arthritis - Product Status 69
  • Table 150: Clarify - Rheumatoid Arthritis - Product Description 69
  • Table 151: SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 152: SOMAscan Assay - Rheumatoid Arthritis - Product Status 70
  • Table 153: SOMAscan Assay - Rheumatoid Arthritis - Product Description 70
  • Table 154: SQI Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 155: Ig_PLEX Rheumatoid Arthritis Panel With Expanded Markers - Product Status 71
  • Table 156: Ig_PLEX Rheumatoid Arthritis Panel With Expanded Markers - Product Description 71
  • Table 157: The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 158: Optilite - C-reactive Protein Test - Product Status 72
  • Table 159: Optilite - C-reactive Protein Test - Product Description 72
  • Table 160: Optilite - High Sensitive C-reactive Protein Kit - Product Status 73
  • Table 161: Optilite - High Sensitive C-reactive Protein Kit - Product Description 73
  • Table 162: Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 163: Phadia 2500 Laboratory System - RF IgM/IgA Test - Product Status 74
  • Table 164: Phadia 2500 Laboratory System - RF IgM/IgA Test - Product Description 75
  • Table 165: Phadia 5000 Laboratory System - CCP Test - Product Status 75
  • Table 166: Phadia 5000 Laboratory System - CCP Test - Product Description 75
  • Table 167: Phadia 5000 Laboratory System - RF IgM/IgA Test - Product Status 76
  • Table 168: Phadia 5000 Laboratory System - RF IgM/IgA Test - Product Description 76
  • Table 169: Toscana Biomarkers Srl Pipeline Products & Ongoing Clinical Trials Overview 77
  • Table 170: Diagnostic Assay - Rheumatoid Arthritis - Product Status 77
  • Table 171: Diagnostic Assay - Rheumatoid Arthritis - Product Description 77
  • Table 172: University Health Network Pipeline Products & Ongoing Clinical Trials Overview 78
  • Table 173: Biomarker Test - Rheumatoid Arthritis - Product Status 78
  • Table 174: Biomarker Test - Rheumatoid Arthritis - Product Description 78
  • Table 175: University of Aberdeen Pipeline Products & Ongoing Clinical Trials Overview 79
  • Table 176: Diagnostic Assay - Rheumatoid Arthritis - Product Status 79
  • Table 177: Diagnostic Assay - Rheumatoid Arthritis - Product Description 79
  • Table 178: University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 179: Molecular Pathology Test - Rheumatoid Arthritis - Product Status 80
  • Table 180: Molecular Pathology Test - Rheumatoid Arthritis - Product Description 80
  • Table 181: University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 182: Biomarker Based Assay - Rheumatoid Arthritis - Product Status 81
  • Table 183: Biomarker Based Assay - Rheumatoid Arthritis - Product Description 81
  • Table 184: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 185: PBMC-Based Companion Diagnostic Test - Product Status 82
  • Table 186: PBMC-Based Companion Diagnostic Test - Product Description 82
  • Table 187: University of Warwick Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 188: Diagnostic Test - Arthritis - Product Status 83
  • Table 189: Diagnostic Test - Arthritis - Product Description 83
  • Table 190: University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview 84
  • Table 191: CD-Medics Test - RA - Product Status 84
  • Table 192: CD-Medics Test - RA - Product Description 84
  • Table 193: Glossary 160

List of Figures

1.2 List of Figures

  • Figure 1: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Stage of Development 11
  • Figure 2: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Segment 12
  • Figure 3: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Territory 13
  • Figure 4: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Regulatory Path 14
  • Figure 5: Rheumatoid - Inflammatory Diseases Markers Tests - Pipeline Products by Estimated Approval Date 15
Back to Top